›› 2014, Vol. 32 ›› Issue (8): 745-.doi: 10.3969 j.issn.1000-3606.2014.08.012

Previous Articles     Next Articles

The MRP1 expression in childhood acute lymphoblastic leukemia and its clinical significance

QIU Baoling1, WU Dong1, HONG Dan1, ZHOU Qi1, LU Jun1, FAN Junjie1, CENG Jiannong2, HU Shaoyan1   

  1. 1. The Children’s Hospital of Soochow University, Suzhou, 215003, Jiangsu, China; 2. The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, 215006, Jiangsu, China
  • Received:2014-08-15 Published:2014-08-15 Online:2014-08-15

Abstract: Objective Multidrug resistance-associated protein 1 (MRP1) has been reported with a close correlation with tumor multi-drug resistance. Real-time quantitative PCR (QRT-PCR) was performed to detect the MRP1 gene expression in childhood acute lymphoblastic leukemia (ALL) and its clinical significance was analyzed. Methods Sixty-seven denovo ALL patients and 10 healthier children as bone marrow donor were studied. The chemotherapy was given according to CCLG-2008 protocol. SPSS software was employed to analyze the data and p-value below 0.05 was regarded as statistic significance. Results MRP1 expression level showed a close correlation with ALL risk, the median of MRP1 expression was 4.28 (2.75~6.12), 5.62 (4.99~8.60) and 7.56 (3.66~11.13) for standard-risk group (SR), intermediate-risk group (IR) and high-risk group (HR), respectively. MRP1 mRNA expression in T-ALL group was 7.71 (6.49~14.35), which is higher than that of B-ALL (5.18(3.89~8.46)) (P<0.01). The rate of leukemia cells’ sensitivity to prednisone on 7th day was 70.6% in high expression group (n=34), which was significantly lower than that in low expression group (n=33, 90.9%, P=0.035). The complete remission rateon 33th day was 64.7% in high expression group, and 87.9% in low expression group, which showed a significant difference between them (P=0.026). Conclusions In children ALL, the expression of MRP1 is closely related with immunophenotyping, treatment response, hazard level and disease relapse.